ERNA
Income statement / Annual
Last year (2025), Ernexa Therapeutics Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2025, Ernexa Therapeutics Inc.'s net income was -$14.08 M.
See Ernexa Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$582.00 K |
$68.00 K |
$0.00 |
$0.00 |
$0.00 |
$19.81 M |
$23.34 M |
$21.27 M |
$22.31 M |
| Cost of Revenue |
$0.00
|
$96.00 K
|
$236.00 K
|
$0.00
|
$0.00
|
$98.00 K
|
$7.84 M
|
$8.39 M
|
$7.09 M
|
$8.13 M
|
| Gross Profit |
$0.00
|
$486.00 K
|
-$168.00 K
|
$0.00
|
$0.00
|
-$98.00 K
|
$11.96 M
|
$14.95 M
|
$14.19 M
|
$14.18 M
|
| Gross Profit Ratio |
0
|
0.84
|
-2.47
|
0
|
0
|
0
|
0.6
|
0.64
|
0.67
|
0.64
|
| Research and Development Expenses |
$4.16 M
|
$4.60 M
|
$5.92 M
|
$10.39 M
|
$12.71 M
|
$3.95 M
|
$26.00 K
|
$72.00 K
|
$139.00 K
|
$0.00
|
| General & Administrative Expenses |
$5.16 M
|
$13.13 M
|
$14.59 M
|
$16.56 M
|
$14.72 M
|
$3.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.16 M
|
$13.13 M
|
$14.59 M
|
$16.56 M
|
$14.72 M
|
$3.30 M
|
$13.15 M
|
$14.41 M
|
$15.45 M
|
$16.46 M
|
| Other Expenses |
$0.00
|
-$1.58 M
|
$461.00 K
|
$6.27 M
|
$86.30 M
|
-$98.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$9.32 M
|
$16.16 M
|
$20.97 M
|
$33.22 M
|
$113.73 M
|
$7.15 M
|
$13.18 M
|
$14.49 M
|
$15.59 M
|
$16.46 M
|
| Cost And Expenses |
$9.32 M
|
$16.26 M
|
$21.20 M
|
$33.22 M
|
$113.73 M
|
$7.25 M
|
$21.02 M
|
$22.87 M
|
$22.68 M
|
$24.59 M
|
| Interest Income |
$83.00 K
|
$249.00 K
|
$138.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$27.00 K
|
$6.75 M
|
$614.00 K
|
$30.00 K
|
$74.00 K
|
$43.00 K
|
$249.00 K
|
$389.00 K
|
$498.00 K
|
$576.00 K
|
| Depreciation & Amortization |
$263.00 K
|
$1.64 M
|
$1.12 M
|
$497.00 K
|
$459.00 K
|
$98.00 K
|
$3.17 M
|
$2.76 M
|
$2.32 M
|
$2.89 M
|
| EBITDA |
-$13.84 M |
-$36.12 M |
-$19.93 M |
-$24.01 M |
-$121.95 M |
-$26.39 M |
$1.40 M |
$3.23 M |
$915.00 K |
$609.00 K |
| EBITDA Ratio |
0
|
-62.06
|
-293.15
|
0
|
0
|
0
|
0.07
|
0.14
|
0.04
|
0.03
|
| Operating Income Ratio |
0
|
-26.93
|
-310.81
|
0
|
0
|
0
|
-0.06
|
0.02
|
-0.07
|
-0.1
|
| Total Other Income/Expenses Net |
-$4.81 M
|
-$28.84 M
|
-$536.00 K
|
$8.68 M
|
-$8.75 M
|
-$19.28 M
|
-$808.00 K
|
-$787.00 K
|
$391.00 K
|
-$607.00 K
|
| Income Before Tax |
-$14.13 M
|
-$44.51 M
|
-$21.67 M
|
-$24.53 M
|
-$122.48 M
|
-$26.53 M
|
-$2.02 M
|
-$323.00 K
|
-$1.01 M
|
-$2.89 M
|
| Income Before Tax Ratio |
0
|
-76.48
|
-318.69
|
0
|
0
|
0
|
-0.1
|
-0.01
|
-0.05
|
-0.13
|
| Income Tax Expense |
-$45.00 K
|
$30.00 K
|
-$3.00 K
|
$45.00 K
|
$64.00 K
|
$0.00
|
$27.00 K
|
-$64.00 K
|
$66.00 K
|
$38.00 K
|
| Net Income |
-$14.08 M
|
-$44.54 M
|
-$21.67 M
|
-$24.58 M
|
-$122.55 M
|
$11.91 M
|
-$2.05 M
|
-$259.00 K
|
-$1.08 M
|
-$2.92 M
|
| Net Income Ratio |
0
|
-76.53
|
-318.65
|
0
|
0
|
0
|
-0.1
|
-0.01
|
-0.05
|
-0.13
|
| EPS |
-56 |
-39.25 |
-102 |
-201.5 |
-1415.25 |
-87.75 |
-712 |
-96.25 |
-441 |
-1536 |
| EPS Diluted |
-56 |
-39.25 |
-102 |
-201.5 |
-1415.25 |
-87.75 |
-712 |
-96.25 |
-441 |
-1536 |
| Weighted Average Shares Out |
$252.28 K
|
$1.14 M
|
$212.56 K
|
$122.04 K
|
$86.60 K
|
$69.31 K
|
$2.88 K
|
$2.69 K
|
$2.44 K
|
$1.90 K
|
| Weighted Average Shares Out Diluted |
$252.28 K
|
$1.14 M
|
$212.56 K
|
$122.04 K
|
$86.60 K
|
$69.31 K
|
$2.88 K
|
$2.69 K
|
$2.44 K
|
$1.90 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
